Having pioneered the introduction of the world's first Bluetooth®-enabled ICM, Abbott is leading innovation once more in arrhythmia management with Assert-IQ ICM. The latest device provides consistent monitoring for abnormal heart rhythms while offering tools designed to improve data management and workflow.

"Assert-IQ is the next generation of implantable cardiac monitors, providing physicians with actionable data and new patient insights," said Professor Paolo Della Bella, M.D., head of the arrhythmia department at IRCCS San Raffaele Scientific Institute in Italy. "The real-time data, advanced algorithms and diagnostic accuracy empower physicians to deliver more personalized and effective care. For those with abnormal heart rhythms, Assert-IQ ICM provides peace of mind and the freedom to live their lives with confidence."


About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals, and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Back to HCB News

Cardiology Homepage